Medline has drawn a second warning letter from the U.S. Food and Drug Administration in as many months, with federal inspectors flagging repeated microbial contamination and other quality-control lapses at the company’s Waukegan drug plant. The latest citation, dated May 28, follows a separate FDA warning in March over defective angiographic syringes and piles more scrutiny on the Chicago-area supplier. Hospital purchasing teams are already watching closely to see whether recalls and cleanup efforts will pinch supplies of kits and devices that rely on Medline components.
According to Reuters, the May 28 letter says FDA investigators found Bacillus cereus in finished drug samples as well as in the plant environment and concluded that earlier corrective steps had fallen short. Regulators ordered Medline to submit an independent risk assessment, a remediation plan with specific timelines and other corrective documentation or face the possibility of regulatory or legal action.
Inside The FDA’s Waukegan Inspection
In its May 28 warning letter (FDA), the agency says inspectors repeatedly isolated B. cereus in both finished-product and environmental samples at the Waukegan facility and logged routine departures from written cleaning and disinfection procedures. The letter directs Medline to carry out a thorough contamination-hazards risk assessment, spell out plans for terminal sterilization or aseptic processing if that proves necessary, and complete a three-year retrospective review of investigations and corrective-and-preventive-action effectiveness. The FDA notes that similar shortcomings surfaced at other Medline locations, signaling broader issues with management oversight across the company’s manufacturing network.
Syringe Troubles Set The Stage
The May warning follows a March action tied to Medline’s NAMIC angiographic syringes, which regulators and the company said could unwind or disconnect from manifolds during cardiac and imaging procedures. As reported by MedTech Dive, that problem generated roughly 250 complaints and dozens of medical device reports, prompting Medline to pull the affected syringes from the market and notify customers.
Medline told Reuters it is “continuing to fully engage with the FDA” on its Waukegan and other drug-manufacturing sites and said it has made “significant improvements in production processes and plant operations” at the ReadyCare Waukegan facility. How the company follows through on those inspections and recall efforts will be watched closely by both regulators and customers.
FDA Turns Up The Heat
The FDA’s May letter (FDA) warns that if Medline does not address the problems adequately and quickly, it could face measures that include product seizure, injunction, withholding of export certificates or disqualification from federal contracts. The agency has asked for a written response within 15 working days outlining the company’s corrective plan and says it may return to re-inspect to verify that fixes are in place. For hospitals, the short-term worry is keeping inventories safe and getting clear guidance on which kits are quarantined, relabeled or otherwise affected.
Hospitals Brace For Supply Headaches
Industry watchers say the run of recalls, warning letters and early alerts has the potential to create fresh operational hassles and limit choices for clinicians who rely on products that include the impacted syringes or related kits. Becker’s Hospital Review has tracked FDA alerts and surgical-kit removals tied to the syringe issue, highlighting the extra legwork hospitals now face to identify, quarantine and relabel inventory that uses Medline components.
.jpg){kind=link}